open access

Vol 11, No 1 (2014)
Review paper
Get Citation

Lurasidone — novel atypical neuroleptic with antidepressant activity

Anna Wasik, Marcin Kołaczkowski, Anna Wesołowska
Psychiatria 2014;11(1):1-8.

open access

Vol 11, No 1 (2014)
Prace poglądowe - nadesłane

Abstract

Lurasidone is a novel second generation antipsychotic (SGA) with antidepressant-like activity, approved by FDA for the treatment of schizophrenia and depressive symptoms in the bipolar disorder type 1 (BP I). Similar to other atypical antipsychotics, lurasidon has a potent affinity for D2, 5-HT2A and 5-HT7 receptors, and moderate for 5-HT1A and alfa2C ones. Using animal models of learning and memory it has been shown that lurasidone displays ability to improve memory dysfunctions caused by MK-801 or fencyclidine and evokes potential antidepressant activity in short- and long-term rodent models of depression. The efficacy and tolerability of lurasidone for treatment of acute and chronic schizophrenia as well as major depressive episodes occurring in BP I have been evaluated in few double-blind randomized, fixed-dose clinical trials. Lurasidone, compared to placebo, showed a significantly greater improvement in reduction of positive and negative symptoms of schizophrenia and core symptoms of depression in BP I. Lurasidone is well tolerated; nausea, somnolence and akathisia are the most common adverse effects (with 5–15% of frequency). In comparison to other SGA, lurasidone seems to have no significant influence on metabolic parameters like glucose and lipids level or QT lenght, producing only slight weight gain in patients. Comfortable dosing (once daily with meal) and wider activity profile make lurasidone a competitive candidate for pharmacotherapy of psychiatric disorders.

Abstract

Lurasidone is a novel second generation antipsychotic (SGA) with antidepressant-like activity, approved by FDA for the treatment of schizophrenia and depressive symptoms in the bipolar disorder type 1 (BP I). Similar to other atypical antipsychotics, lurasidon has a potent affinity for D2, 5-HT2A and 5-HT7 receptors, and moderate for 5-HT1A and alfa2C ones. Using animal models of learning and memory it has been shown that lurasidone displays ability to improve memory dysfunctions caused by MK-801 or fencyclidine and evokes potential antidepressant activity in short- and long-term rodent models of depression. The efficacy and tolerability of lurasidone for treatment of acute and chronic schizophrenia as well as major depressive episodes occurring in BP I have been evaluated in few double-blind randomized, fixed-dose clinical trials. Lurasidone, compared to placebo, showed a significantly greater improvement in reduction of positive and negative symptoms of schizophrenia and core symptoms of depression in BP I. Lurasidone is well tolerated; nausea, somnolence and akathisia are the most common adverse effects (with 5–15% of frequency). In comparison to other SGA, lurasidone seems to have no significant influence on metabolic parameters like glucose and lipids level or QT lenght, producing only slight weight gain in patients. Comfortable dosing (once daily with meal) and wider activity profile make lurasidone a competitive candidate for pharmacotherapy of psychiatric disorders.

Get Citation

Keywords

atypical antipsychotic, schizophrenia, bipolar disorder

About this article
Title

Lurasidone — novel atypical neuroleptic with antidepressant activity

Journal

Psychiatria (Psychiatry)

Issue

Vol 11, No 1 (2014)

Article type

Review paper

Pages

1-8

Bibliographic record

Psychiatria 2014;11(1):1-8.

Keywords

atypical antipsychotic
schizophrenia
bipolar disorder

Authors

Anna Wasik
Marcin Kołaczkowski
Anna Wesołowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl